TW429255B - Pyrazine compounds having treatment of central nervous system diseases and disorders - Google Patents
Pyrazine compounds having treatment of central nervous system diseases and disordersInfo
- Publication number
- TW429255B TW429255B TW088114723A TW88114723A TW429255B TW 429255 B TW429255 B TW 429255B TW 088114723 A TW088114723 A TW 088114723A TW 88114723 A TW88114723 A TW 88114723A TW 429255 B TW429255 B TW 429255B
- Authority
- TW
- Taiwan
- Prior art keywords
- disorders
- treatment
- nervous system
- central nervous
- system diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9818881.6A GB9818881D0 (en) | 1998-08-28 | 1998-08-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW429255B true TW429255B (en) | 2001-04-11 |
Family
ID=10838055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW088114723A TW429255B (en) | 1998-08-28 | 1999-08-27 | Pyrazine compounds having treatment of central nervous system diseases and disorders |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6503909B1 (zh) |
| EP (1) | EP1107960A1 (zh) |
| JP (1) | JP2002523499A (zh) |
| KR (1) | KR20010079696A (zh) |
| CN (1) | CN1324349A (zh) |
| AU (1) | AU5624999A (zh) |
| BR (1) | BR9913183A (zh) |
| CA (1) | CA2341543A1 (zh) |
| CO (1) | CO5130006A1 (zh) |
| GB (1) | GB9818881D0 (zh) |
| MA (1) | MA26681A1 (zh) |
| PE (1) | PE20001022A1 (zh) |
| TR (1) | TR200100603T2 (zh) |
| TW (1) | TW429255B (zh) |
| WO (1) | WO2000012488A1 (zh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6995161B2 (en) | 2000-02-16 | 2006-02-07 | Neurogen Corporation | Substituted arylpyrazines |
| EP1500653A1 (en) * | 2000-02-16 | 2005-01-26 | Neurogen Corporation | Substituted arylpyrazines |
| GB0010971D0 (en) * | 2000-05-05 | 2000-06-28 | Glaxo Group Ltd | Process |
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| CA2484209C (en) * | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7179807B2 (en) | 2002-08-20 | 2007-02-20 | Neurogen Corporation | 5-substituted-2-arylpyrazines |
| BRPI0411552A (pt) * | 2003-06-16 | 2006-08-01 | Celltech R & D Inc | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea |
| US20070287677A1 (en) * | 2004-03-30 | 2007-12-13 | Genomldea Inc. | Rad51 Expression Inhibitors, Pharmaceutical Agents Containing The Inhibitors As Active Ingredients, And Uses Thereof |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2094731A2 (en) * | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
| EP2097450A2 (en) * | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| JP2011506483A (ja) * | 2007-12-14 | 2011-03-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた骨折の治療方法 |
| KR20230135541A (ko) * | 2022-03-16 | 2023-09-25 | (주)아름테라퓨틱스 | 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도 |
| CN115611700A (zh) * | 2022-10-11 | 2023-01-17 | 辽宁东大光明化工科技有限责任公司 | 一种1-溴-2,5-二氯-3-氟苯的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3575975A (en) * | 1968-07-25 | 1971-04-20 | Merck & Co Inc | Process for the preparation of 3-aminopyrazinoylureas |
| US3544568A (en) * | 1969-03-18 | 1970-12-01 | Merck & Co Inc | 3-amino-5,6-substituted pyrazinamides |
| US4402958A (en) | 1981-11-19 | 1983-09-06 | American Cyanamid Company | Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates |
| MA26473A1 (fr) | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
-
1998
- 1998-08-28 GB GBGB9818881.6A patent/GB9818881D0/en not_active Ceased
-
1999
- 1999-08-26 KR KR1020017002509A patent/KR20010079696A/ko not_active Application Discontinuation
- 1999-08-26 TR TR2001/00603T patent/TR200100603T2/xx unknown
- 1999-08-26 CN CN99812550A patent/CN1324349A/zh active Pending
- 1999-08-26 PE PE1999000868A patent/PE20001022A1/es not_active Application Discontinuation
- 1999-08-26 CA CA002341543A patent/CA2341543A1/en not_active Abandoned
- 1999-08-26 AU AU56249/99A patent/AU5624999A/en not_active Abandoned
- 1999-08-26 EP EP99942919A patent/EP1107960A1/en not_active Withdrawn
- 1999-08-26 BR BR9913183-8A patent/BR9913183A/pt not_active Application Discontinuation
- 1999-08-26 JP JP2000567518A patent/JP2002523499A/ja active Pending
- 1999-08-26 US US09/762,295 patent/US6503909B1/en not_active Expired - Fee Related
- 1999-08-26 WO PCT/EP1999/006248 patent/WO2000012488A1/en not_active Application Discontinuation
- 1999-08-27 CO CO99054338A patent/CO5130006A1/es unknown
- 1999-08-27 TW TW088114723A patent/TW429255B/zh not_active IP Right Cessation
- 1999-08-27 MA MA25746A patent/MA26681A1/fr unknown
-
2002
- 2002-08-12 US US10/216,399 patent/US20030022904A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CO5130006A1 (es) | 2002-02-27 |
| TR200100603T2 (tr) | 2001-07-23 |
| WO2000012488A1 (en) | 2000-03-09 |
| EP1107960A1 (en) | 2001-06-20 |
| PE20001022A1 (es) | 2000-10-16 |
| CA2341543A1 (en) | 2000-03-09 |
| CN1324349A (zh) | 2001-11-28 |
| GB9818881D0 (en) | 1998-10-21 |
| BR9913183A (pt) | 2001-05-15 |
| KR20010079696A (ko) | 2001-08-22 |
| US6503909B1 (en) | 2003-01-07 |
| US20030022904A1 (en) | 2003-01-30 |
| JP2002523499A (ja) | 2002-07-30 |
| MA26681A1 (fr) | 2004-12-20 |
| AU5624999A (en) | 2000-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW429255B (en) | Pyrazine compounds having treatment of central nervous system diseases and disorders | |
| TW369526B (en) | Diazabicyclic neurokinin antagonists | |
| HUT59081A (en) | Process for producing aryl- and heteroaryl-ethylene derivatives and pharmaceutical compositions containing them | |
| LU91587I2 (fr) | Agomélatine et ses dérivés pharmaceutiquement acceptables (VALDOXAN) | |
| UA27467C2 (uk) | ПОХІДНІ ІНДОЛУ ЯК 5-НТ<sub>1</sub> АГОНІСТИ ТА ПРОМІЖНІ СПОЛУКИ | |
| TW368501B (en) | 7-(2-aminoethyl)-benzothiazolones | |
| ATE35137T1 (de) | Thieno(2,3-d)pyrimidin-derivate und deren salze. | |
| MY117092A (en) | Chemotherapeutic pyrrolocarbazole derivatives | |
| PL328224A1 (en) | Novel derivatives of 2,3-benzodiazepin, yheir production and use as medicines | |
| ES8707951A1 (es) | Derivados de tetrazol | |
| TW334428B (en) | Novel benzodiazepine derivatives | |
| GR78774B (zh) | ||
| ES8607265A1 (es) | Un procedimiento para la preparacion de nuevos derivados de aminoalcoholes | |
| PT1049672E (pt) | Derivados de azetidinocarboxamida para o tratamento de disturbios do snc | |
| ES8701762A1 (es) | Un procedimiento para preparar nuevos derivados de 5-(w-fe- netilamino-alquil)-4,5,6,7-tetrahidro-tieno-(3,2-c)-piridina | |
| SE8901060D0 (sv) | New compounds | |
| ATE18993T1 (de) | Dibenzocycloheptenyliden-verbindungen zur verwendung bei der modulation der immunreaktion. | |
| DK0784973T3 (da) | Quinoxalinderivater til behandling af tinnitus | |
| ES473775A1 (es) | Perfeccionamientos en o relacionados con compuestos organi- cos | |
| AU2178199A (en) | Azetidinecarboxamide derivatives for the treatment of cns disorders | |
| ES2112470T3 (es) | Derivados de piridazinona, procedimientos de produccion y utilizacion. | |
| EP0461264A4 (en) | Ethynylphenyl derivative, production thereof, and remedy for diseases of circulatory organs containing the same as active ingredient | |
| ES8701144A1 (es) | Un procedimiento para preparar un derivado de tetrahidronaf-taleno | |
| SE8701524D0 (sv) | Nya sulfonamider och deras framstellningsforfarande | |
| MY104630A (en) | 4(1h) ouinoline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |